These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A review of the efficacy and tolerability of venlafaxine. Dierick M Eur Psychiatry; 1997; 12 Suppl 4():307s-13s. PubMed ID: 19698585 [TBL] [Abstract][Full Text] [Related]
5. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Holliday SM; Benfield P Drugs; 1995 Feb; 49(2):280-94. PubMed ID: 7729333 [TBL] [Abstract][Full Text] [Related]
6. The role of venlafaxine in rational antidepressant therapy. Feighner JP J Clin Psychiatry; 1994 Sep; 55 Suppl A():62-8; discussion 69-70, 98-100. PubMed ID: 7961545 [TBL] [Abstract][Full Text] [Related]
7. The Role of Metabolites of Antidepressants in the Treatment of Depression. Rudorfer MV; Potter WZ CNS Drugs; 1997 Apr; 7(4):273-312. PubMed ID: 27520753 [TBL] [Abstract][Full Text] [Related]
8. Mirtazapine : A Review of its Pharmacology and Therapeutic Potential in the Management of Major Depression. Davis R; Wilde MI CNS Drugs; 1996 May; 5(5):389-402. PubMed ID: 26071050 [TBL] [Abstract][Full Text] [Related]
9. Subchronic antidepressant treatment with venlafaxine or imipramine and effects on blood pressure and heart rate: assessment by automatic 24-hour monitoring. Gründer G; Wetzel H; Schlösser R; Benkert O Pharmacopsychiatry; 1996 Mar; 29(2):72-8. PubMed ID: 8741025 [TBL] [Abstract][Full Text] [Related]
10. The treatment of depression with different formulations of venlafaxine: a comparative analysis. Olver JS; Burrows GD; Norman TR Hum Psychopharmacol; 2004 Jan; 19(1):9-16. PubMed ID: 14716706 [TBL] [Abstract][Full Text] [Related]
11. Optimizing antidepressant treatment: efficacy and tolerability. Deakin B; Dursun S Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S13-24. PubMed ID: 12369607 [TBL] [Abstract][Full Text] [Related]
12. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. Seo HJ; Sohi MS; Patkar AA; Masand PS; Pae CU Postgrad Med; 2010 Jan; 122(1):125-38. PubMed ID: 20107296 [TBL] [Abstract][Full Text] [Related]
13. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035 [TBL] [Abstract][Full Text] [Related]
14. Venlafaxine: a structurally unique and novel antidepressant. Morton WA; Sonne SC; Verga MA Ann Pharmacother; 1995 Apr; 29(4):387-95. PubMed ID: 7633018 [TBL] [Abstract][Full Text] [Related]
15. Antidepressant drug selection: criteria and options. Preskorn SH J Clin Psychiatry; 1994 Sep; 55 Suppl A():6-22; discussion 23-4, 98-100. PubMed ID: 7961544 [TBL] [Abstract][Full Text] [Related]
16. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. Schueler YB; Koesters M; Wieseler B; Grouven U; Kromp M; Kerekes MF; Kreis J; Kaiser T; Becker T; Weinmann S Acta Psychiatr Scand; 2011 Apr; 123(4):247-65. PubMed ID: 20831742 [TBL] [Abstract][Full Text] [Related]